Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia

Hiroaki Goto¹ · Yuki Yoshino¹ · Mieko Ito¹ · Junichi Nagai² · Tadashi Kumamoto³ · Takeshi Inukai⁴ · Yukari Sakurai¹ · Naoyuki Miyagawa¹ · Dai Keino¹ · Tomoko Yokosuka¹ · Fuminori Iwasaki¹ · Satoshi Hamanoue¹ · Masae Shiomi¹ · Shoko Goto¹

Published online: 18 July 2021
 © Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to:
Cancer Chemotherapy and Pharmacology
(2020) 85:773–783
<https://doi.org/10.1007/s00280-020-04045-9>

In the original publication of the article, two errors were found in Table 1 and Table 2 in the supplementary file. The corrected tables are given below:

Supplemental table 1; Characteristics of patients who provided samples originating newly established cell lines

Cell line	Age at sampling /Gender	diagnosis	Karyotype	Fusion gene
KCB2	1y8m/F	BCP-ALL	46, XX, t(8;14)(q24;q32), add(10)(q22)	IgH/c-Myc
KCB4	3y11m/M	BCP-ALL	46,XY,t(1;3)(p22;q27)	ND
KCB6	1y9m/M	BCP-ALL	46, XY, dup(1)(p11p32), t(8;14)(q24;q32), der(14),t(1;14)(q10;q10)	IgH/c-Myc
KCB7	14y3m/M	BCP-ALL	46,XY, del(9)(p?),t(14;18)(q32;q21)	IgH/Bcl2
KCB9	17y5m/F	BCP-ALL	49, XX, add(1)(q32), t(1;7)(p32;q22), add(2)(p11.2), add(9)(p13), +20, -21, +mar1, +mar2, +mar3	MEF2D/Bcl9
KCB10	17y0m/F	BCP-ALL	47, XX, +r1	ND

Abbreviations; y: years, m: months, F; female, M; male, BCP-ALL: B cell precursor acute lymphoblastic leukemia, ND: not determined

The original article can be found online at <https://doi.org/10.1007/s00280-020-04045-9>.

✉ Hiroaki Goto
 hgotou@kcmc.jp

¹ Division of Hematology/Oncology, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa Minami-Ku, Yokohama, Japan

² Department of Laboratory Medicine, Kanagawa Children's Medical Center, Yokohama, Japan

³ Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan

⁴ Department of Pediatrics, School of Medicine, Yamanashi University, Kofu, Japan

Supplemental table 2; names and concentrations of drugs used in the high throughput drug sensitivity test

Drug	Final concentration (top dose)	Drug	Final concentration (top dose)	Drug	Final concentration (top dose)
Dexamethasone ¹	100 µg/ml	Regorafenib ³	1 µM	Saracatinib ³	1 µM
Clofarabine ⁶	100 ng/ml	Lenvatinib ³	1 µM	ICG-001 ³	1 µM
Eribulin ⁶	5 ng/ml	Lapatinib ³	1 µM	Sonidegib ³	1 µM
SN38 ²	20 ng/ml	Erlotinib ³	1 µM	ABT-199 ³	1 µM
Cytarabine ²	100 µg/ml	Crenolanib ³	1 µM	YM155 ³	1 µM
Etoposide ²	20 µg/ml	Ibrutinib ³	1 µM	Tanespimycin ³	1 µM
L-Asparaginase ⁴	10 U/ml	Tandutinib ³	1 µM	Elesclomol ³	1 µM
Carboplatin ¹	10 µg/ml	Crizotinib ³	1 µM	PX-478 2HCl ³	1 µM
Temozolomide ¹	5 µg/ml	Volasertib ³	1 µM	2-Methoxyestradiol ³	1 µM
Vinblastine ²	10 ng/ml	GW843682X ²	1 µM	Chrysin Dimethylether ²	10 µg/ml
Docetaxel ³	1 µg/ml	Barasertib-HQPA ³	1 µM	Quercetin ³	1 µM
Vincristine ³	1 µg/ml	Trametinib ³	1 µM	RG-7112 ³	1 µM
4-HO-CY ²	40 µg/ml	Selumetinib	1 µM	MI-773 ³	1 µM
Mitoxantrone ¹	500 ng/ml	Vemurafenib ³	1 µM	Bortezomib ³	50 ng/ml
Topotecan ⁷	500 ng/ml	Dabrafenib ³	1 µM	Carfilzomib ³	1 µM
Ara-G hydrate ⁴	88.5 µM	CEP-701 ²	1 µM	Z-LLNle-CHO ⁵	1 µM
Fludarabine ³	5 µg/ml	Gilteritinib ³	1 µM	RO4929097 ³	1 µM
Azacitidine ²	1 µg/ml	Everolimus ³	1 µM	GSK269962A ³	1 µM
Decitabine ³	1 µM	Rapamycin ³	1 µM	AZD7762 ³	1 µM
EPZ005687 ³	1 µM	Perifosine ³	1 µM	AZD1208 ³	1 µM
Tazemetostat ³	1 µM	Idelalisib ³	1 µM	Selisistat ³	1 µM
Vorinostat ³	1 µM	PI-103 ³	1 µM	Apabetalone ³	1 µM
Panobinostat ³	1 µM	AZD1480 ³	1 µM	Pinometostat ³	1 µM
Olaparib ³	1 µM	Ruxolitinib ³	1 µM	GSK2879552 2HCl ³	1 µM
Linifanib ³	1 µM	Ponatinib ³	1 µM	Linistatin ³	1 µM
Pazopanib ³	1 µM	Imatinib ³	1 µM	Palbociclib ³	1 µM
Sorafenib ³	1 µM	Dasatinib ³	1 µM		

Abbreviations; 4-HO-CY: 4-hydroperoxy cyclophosphamide, HQPA: hydroxyquinazoline pyrazol anilide. Drugs were purchased from 1: FUJIFILM Wako Pure Chemical Co. (Osaka, Japan), 2: Funakoshi Co. (Tokyo, Japan), 3: Selleck Chemicals (Houston, TX), 4: Sigma-Aldrich Co. (St. Luis, MO), 5: Abcam (Cambridge, UK), 6: Adooq Bioscience (Irvine, CA), 7: Cayman Chemical (Ann Arbor, MI), 8: Funakoshi Co. and provision from Eisai Co. (Tokyo, Japan).

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.